Form 4: Ultragenyx Director Sanders Acquires Stock and Options

Director Corazon (Corsee) D. Sanders of Ultragenyx Pharmaceutical Inc. reports acquisition of common stock and stock options.

Summary

• On May 15, 2025, Corazon (Corsee) D. Sanders, a director of Ultragenyx Pharmaceutical Inc., acquired 5,740 shares of common stock and options to purchase 10,787 shares of common stock.
• The 5,740 shares were acquired through an award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
• The RSUs will vest on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
• The option to purchase 10,787 shares at $34.84 also vests on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
• Following these transactions, Sanders directly owns 17,749 shares of common stock and options to purchase 10,787 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard regulatory filing reflecting stock and option awards to a director. It doesn't inherently indicate positive or negative news, but rather provides transparency into insider transactions.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates

Keywords

Ultragenyx, Director, Sanders, Stock Options, RSUs, Form 4, Acquisition, Beneficial Ownership